NextCure and Simcere’s CDH6 ADC SIM0505 to Present Phase 1 Data at ASCO 2026
Event summary
- NextCure and Simcere’s SIM0505 (CDH6 ADC) abstract accepted for ASCO 2026 meeting, scheduled for May 29 – June 2 in Chicago.
- SIM0505 is an investigational ADC targeting Cadherin-6 (CDH6) with a proprietary topoisomerase 1 inhibitor (TOPOi) payload.
- Ongoing Phase 1 study (NCT06792552) evaluating SIM0505 in advanced solid tumors, including platinum-resistant ovarian cancer.
- NextCure holds exclusive global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan, retained by Simcere.
The big picture
The acceptance of SIM0505’s abstract for ASCO 2026 underscores the growing focus on targeted therapies in oncology, particularly ADCs. This collaboration between NextCure and Simcere highlights the strategic importance of global partnerships in advancing novel cancer treatments. The Phase 1 data presentation will be critical in assessing the therapeutic potential of SIM0505 in platinum-resistant ovarian cancer and other advanced solid tumors.
What we're watching
- Clinical Efficacy
- How the Phase 1 data for SIM0505 will impact its development trajectory and potential market positioning.
- Regulatory Pathway
- Whether the ASCO presentation will accelerate regulatory discussions for SIM0505.
- Commercial Strategy
- The pace at which NextCure and Simcere can advance SIM0505 through subsequent clinical phases.
Related topics